Ticker > Company >

Cresanto Global share price

Cresanto Global Ltd.

BSE: 531207 SECTOR: Pharmaceuticals & Drugs  7835   8   0

3.48
+0.16 (4.82%)
BSE: 16 Jun 4:00 PM

Price Summary

Today's High

₹ 3.48

Today's Low

₹ 3.48

52 Week High

₹ 3.48

52 Week Low

₹ 2.5

FinStar is Suspended!

FinStar can not be assigned to this company due to its dicey outlook and insufficient data. We will update the FinStar for this company as soon as the data is updated from its end.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

1.49 Cr.

Enterprise Value

1.49 Cr.

No. of Shares

0.43 Cr.

P/E

0

P/B

0

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  -6.13

CASH

0 Cr.

DEBT

0 Cr.

Promoter Holding

32.27 %

EPS (TTM)

₹  -0.42

Sales Growth

0%

ROE

0 %

ROCE

0%

Profit Growth

40.55 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 YearNA
3 YearNA
5 YearNA

Profit Growth

1 Year40.55%
3 Year-19.4%
5 Year-36.69%

ROE%

1 Year0%
3 Year0%
5 Year0%

ROCE %

1 Year0%
3 Year0%
5 Year-39.97%

Debt/Equity

0

Price to Cash Flow

-24.51

Interest Cover Ratio

0

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2025 32.27 0.00
Dec 2024 28.36 0.00
Sep 2024 28.36 0.00
Jun 2024 28.36 0.00
Mar 2024 28.36 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 0 days.

 Limitations

  • The company has shown a poor profit growth of -19.4040010741086% for the Past 3 years.
  • Company has a poor ROE of 0% over the past 3 years.
  • Company has a poor ROCE of 0% over the past 3 years
  • Company has negative cash flow from operations of -0.060686.
  • The company has a low EBITDA margin of 0% over the past 5 years.
  • The company has negative book value.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 0 0 0 0 0
Total Expenditure 0.05 0.02 0.02 0.26 0.33
Operating Profit -0.05 -0.02 -0.02 -0.26 -0.33
Other Income 0 0 0 0.01 0.52
Interest 0 0 0 0 0.12
Depreciation 0 0 0 0 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.05 -0.02 -0.02 -0.25 0.07
Tax 0 0 0 0 0
Profit After Tax -0.05 -0.02 -0.02 -0.25 0.07
Adjusted EPS (Rs) -0.12 -0.04 -0.04 -0.58 0.16

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 0 0 0 0 0
Total Expenditure 0.06 0.07 0.08 0.19 0.1
Operating Profit -0.06 -0.07 -0.08 -0.19 -0.1
Other Income 0.01 0.01 0 0.02 0
Interest 0 0 0 0 0
Depreciation 0.01 0.01 0.01 0.01 0
Exceptional Items 0 0 0 0 0
Profit Before Tax -0.06 -0.07 -0.08 -0.17 -0.1
Tax 0 0 0 0 0
Net Profit -0.06 -0.07 -0.08 -0.17 -0.1
Adjusted EPS (Rs.) -0.13 -0.16 -0.19 -0.4 -0.24

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 4.27 4.27 4.27 4.27 4.27
Total Reserves -6.26 -6.33 -6.41 -6.58 -6.68
Borrowings 0 0 0 0 0
Other N/C liabilities 0 0 2.21 2.37 2.43
Current liabilities 2.24 2.3 0.17 0.09 0.13
Total Liabilities 0.26 0.25 0.25 0.16 0.15
Assets
Net Block 0.17 0.16 0.16 0.15 0.15
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 0 0 0 0 0
Other N/C Assets 0 0 0 0 0
Current Assets 0.09 0.09 0.09 0.01 0.01
Total Assets 0.26 0.25 0.25 0.16 0.15
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -0.06 -0.07 -0.08 -0.17 -0.1
Adjustment 0.01 0.01 0.01 0.07 0.04
Changes in Assets & Liabilities 0.05 0.06 -2.13 -0.06 0
Tax Paid 0 0 0 0 0
Operating Cash Flow 0 0 -2.21 -0.16 -0.06
Investing Cash Flow 0 0 2.21 0.16 0.06
Financing Cash Flow 0 0 0 0 0
Net Cash Flow 0 0 0 0 0

Corporate Actions

Investors Details

PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
promoters 28.36 28.36 28.36 28.36 32.27
hitesh bajoria - - - - 6.68
nishant n bajaj - - - - 9.05
prashant nathmal bajaj - - - - 7.09
tushar pandit awate - - - - 4.73
urmila hansraj sharma - - - - 4.73
ajai goyal 28.36 28.36 28.36 28.36 -
PARTICULARS Mar 2024% Jun 2024% Sep 2024% Dec 2024% Mar 2025%
investors 71.64 71.64 71.64 71.64 67.73
amzel limited 7.02 7.02 7.02 7.02 7.02
carnation corporate consu... - - - - 2.46
chandresh shantilal shah 1.14 1.14 1.14 1.14 1.14
first global stockbroking... 1.65 1.18 1.18 1.18 1.18
mandeep kapur 3.39 3.39 3.39 3.39 3.39
shailesh natvarlal gandhi... 3.66 3.66 3.66 3.66 3.66
carnation corporate consu... - - - 2.46 -
hitesh bajoria - - 1.96 1.96 -
nishant n bajaj - - 1.96 1.96 -
nord asia investment ltd 4.68 4.68 4.68 4.68 -
carnation corporate consu... - - 2.46 - -
carnation commodities pvt... - 2.46 - - -
hemant dembla 2.32 2.32 - - -
meghna dembla 1.59 1.59 - - -
carnation corporate consu... 2.46 - - - -

Ratings & Research Reports

No Credit and Research reports exist for this company.Report us

Company Presentations

Currently we do not have any Presentation and Concall related to this company.Report us

Company News

Raymed Labs informs about newspaper publication 24 May, 1:26 PM Cresanto Global - Quaterly Results 22 May, 5:50 PM Cresanto Global - Quaterly Results 22 May, 5:50 PM Raymed Labs informs about disclosure 27 Feb, 2:25 PM Raymed Labs informs about disclosure 27 Feb, 1:18 PM Raymed Labs informs about disclosure 27 Feb, 1:17 PM Raymed Labs informs about disclosure 19 Feb, 5:30 PM Raymed Labs informs about disclosure 19 Feb, 12:51 PM Raymed Labs informs about disclosure 19 Feb, 12:49 PM Raymed Labs informs about integrated filing 14 Feb, 2:58 PM Raymed Labs informs about post offer public announcement 6 Feb, 1:02 PM Raymed Labs - Quaterly Results 27 Jan, 8:04 PM Raymed Labs - Quaterly Results 27 Jan, 8:04 PM Raymed Labs informs about open offer 14 Jan, 5:04 PM Raymed Labs - Quaterly Results 6 Nov, 5:48 PM Raymed Labs - Quaterly Results 6 Nov, 5:48 PM Raymed Labs informs about newspaper advertisement 23 Aug, 11:11 AM Raymed Labs - Quaterly Results 12 Aug, 6:00 PM Raymed Labs - Quaterly Results 12 Aug, 6:00 PM Raymed Labs informs about newspaper advertisement 25 May, 2:21 PM Raymed Labs informs about newspaper advertisement 25 May, 12:38 PM Raymed Labs - Quaterly Results 24 May, 4:33 PM Raymed Labs - Quaterly Results 24 May, 4:33 PM Raymed Labs - Quaterly Results 24 May, 4:33 PM Raymed Labs informs about board meeting 13 May, 5:30 PM Raymed Labs - Quaterly Results 6 Feb, 12:41 PM Raymed Labs - Quaterly Results 6 Feb, 12:41 PM Raymed Labs - Quaterly Results 6 Feb, 12:41 PM Raymed Labs - Quaterly Results 4 Nov, 1:18 PM Raymed Labs - Quaterly Results 4 Nov, 1:18 PM Raymed Labs - Quaterly Results 4 Nov, 1:18 PM Raymed Labs informs about press release 8 Aug, 2:46 PM Raymed Labs - Quaterly Results 2 Aug, 4:37 PM Raymed Labs - Quaterly Results 2 Aug, 4:37 PM Raymed Labs - Quaterly Results 2 Aug, 4:37 PM Raymed Labs - Quaterly Results 7 Feb, 4:47 PM Raymed Labs - Quaterly Results 7 Feb, 4:47 PM Raymed Labs - Quaterly Results 7 Feb, 4:47 PM Raymed Labs - Quaterly Results 8 Aug, 5:55 PM Raymed Labs - Quaterly Results 8 Aug, 5:55 PM Raymed Labs informs about certificate 18 Apr, 3:07 PM Raymed Labs - Quaterly Results 11 Feb, 12:53 PM Raymed Labs - Quaterly Results 11 Feb, 12:53 PM Raymed Labs informs about resignation of CS cum CO 6 Jan, 2:47 PM Raymed Labs informs about compliance certificate 15 Jul, 5:18 PM Raymed Labs informs about certificate 13 Jan, 11:17 AM Raymed Labs informs about PCS certificate 26 Oct, 1:18 PM

Cresanto Global Stock Price Analysis and Quick Research Report. Is Cresanto Global an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Cresanto Global and its performance over the period of time. Cresanto Global stock price today is Rs 3.48.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Cresanto Global cash from the operating activity was Rs -0.060686 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Cresanto Global has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Cresanto Global , the EPS growth was 40.55 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Cresanto Global has OPM of 0 % which is a bad sign for profitability.
     
  • ROE: Cresanto Global have a poor ROE of 0 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Cresanto Global is Rs 3.48. One can use valuation calculators of ticker to know if Cresanto Global share price is undervalued or overvalued.
Last Updated on:
Brief about Cresanto Global
X